Blood:血友病患者颅内出血的发生率和致死率

2022-02-07 Nebula MedSci原创

与一般人群相比,血友病患者颅内出血的发生率和死亡率均明显更高。

中心点:与一般人群相比,血友病患者颅内出血的发生率和死亡率均明显更高。

A型血友病和B型血友病是一种以X染色体-连锁的方式遗传的凝血因子VIII(FVIII)或IX(FIX)缺乏为特征的出血性疾病。颅内出血 (ICH) 是血友病患者中较为常见的一种严重并发症

近期,国际一流期刊《血液》上发表了一篇Meta分析“Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis”,汇总分析了颅内出血在血友病患者中的发生率和致死率。

研究人员采用与“血友病”、“颅内出血”或“死亡率”相关的词条系统地检索了PubMed和EMBASE数据库,纳入了评估血友病患者颅内出血发生率或死亡率且患者人数≥50的研究,在三个年龄组(所有年龄段的血友病患者、儿童和25岁以下年轻患者、新生儿血友病患者)中分别汇总计算了血友病患者颅内出血的发生率和死亡率。

血友病患者颅内出血的发生率和死亡率的汇总数据

筛选到45项符合要求的研究,共涵盖54470位患者,共随访了809151人·年,包括5326名新生儿。在所有年龄段患者人群中,颅内出血的发生率和死亡率分别是2.3(95% CI 1.2-4.8)和0.8(0.5-1.2)/1000人·年。在儿童和年轻患者中,颅内出血的发生率和死亡率分别是7.4 (95% CI 4.9-11.1)和0.5 (95% CI 0.3-0.9)/1000人·年。在确诊血友病的新生儿中,颅内出血的累积发生率是2.1%(95% CI 1.5-2.8)/100次活产。35%-58%的颅内出血都是自发性的。

综上,该研究结果证实,颅内出血可发生在任何年龄的血友病患者,严重威胁血友病患者的生命安全,需要采取适当的预防措施。

原始出处:

Anne-Fleur Zwagemaker, et al. Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. Blood. December 30, 2021. https://doi.org/10.1182/blood.2021011849.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826771, encodeId=2d211826e7180, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Sep 05 14:22:53 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941802, encodeId=6c2119418023f, content=<a href='/topic/show?id=aaa686456e2' target=_blank style='color:#2F92EE;'>#致死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86456, encryptionId=aaa686456e2, topicName=致死率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Mar 29 18:22:53 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193276, encodeId=1d2b11932e633, content=已学习,新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Mon Feb 14 12:35:40 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193185, encodeId=35f2119318502, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Feb 14 07:11:15 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193118, encodeId=9dc51193118d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba972037990, createdName=1861e90876m, createdTime=Sun Feb 13 22:17:30 CST 2022, time=2022-02-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826771, encodeId=2d211826e7180, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Sep 05 14:22:53 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941802, encodeId=6c2119418023f, content=<a href='/topic/show?id=aaa686456e2' target=_blank style='color:#2F92EE;'>#致死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86456, encryptionId=aaa686456e2, topicName=致死率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Mar 29 18:22:53 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193276, encodeId=1d2b11932e633, content=已学习,新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Mon Feb 14 12:35:40 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193185, encodeId=35f2119318502, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Feb 14 07:11:15 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193118, encodeId=9dc51193118d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba972037990, createdName=1861e90876m, createdTime=Sun Feb 13 22:17:30 CST 2022, time=2022-02-13, status=1, ipAttribution=)]
    2022-03-29 axin009
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826771, encodeId=2d211826e7180, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Sep 05 14:22:53 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941802, encodeId=6c2119418023f, content=<a href='/topic/show?id=aaa686456e2' target=_blank style='color:#2F92EE;'>#致死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86456, encryptionId=aaa686456e2, topicName=致死率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Mar 29 18:22:53 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193276, encodeId=1d2b11932e633, content=已学习,新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Mon Feb 14 12:35:40 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193185, encodeId=35f2119318502, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Feb 14 07:11:15 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193118, encodeId=9dc51193118d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba972037990, createdName=1861e90876m, createdTime=Sun Feb 13 22:17:30 CST 2022, time=2022-02-13, status=1, ipAttribution=)]
    2022-02-14 ms3000000637975859

    已学习,新知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1826771, encodeId=2d211826e7180, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Sep 05 14:22:53 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941802, encodeId=6c2119418023f, content=<a href='/topic/show?id=aaa686456e2' target=_blank style='color:#2F92EE;'>#致死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86456, encryptionId=aaa686456e2, topicName=致死率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Mar 29 18:22:53 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193276, encodeId=1d2b11932e633, content=已学习,新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Mon Feb 14 12:35:40 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193185, encodeId=35f2119318502, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Feb 14 07:11:15 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193118, encodeId=9dc51193118d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba972037990, createdName=1861e90876m, createdTime=Sun Feb 13 22:17:30 CST 2022, time=2022-02-13, status=1, ipAttribution=)]
    2022-02-14 学医无涯

    学习一下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1826771, encodeId=2d211826e7180, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Sep 05 14:22:53 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941802, encodeId=6c2119418023f, content=<a href='/topic/show?id=aaa686456e2' target=_blank style='color:#2F92EE;'>#致死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86456, encryptionId=aaa686456e2, topicName=致死率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Mar 29 18:22:53 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193276, encodeId=1d2b11932e633, content=已学习,新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Mon Feb 14 12:35:40 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193185, encodeId=35f2119318502, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Feb 14 07:11:15 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193118, encodeId=9dc51193118d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba972037990, createdName=1861e90876m, createdTime=Sun Feb 13 22:17:30 CST 2022, time=2022-02-13, status=1, ipAttribution=)]
    2022-02-13 1861e90876m

    学习了

    0

相关资讯

BioMarin公司血友病基因疗法Ⅲ期临床5年的长期效果观察,数据积极

BioMarin的疗法,称为valoctocogene roxaparvovec或'valrox',在第3阶段GENER8-1试验中,20名严重A型血友病成人患者中,8名凝血因子VIII的水平得到充分

 Haemophilia: 血友病患者中内皮糖蛋白水平升高与血管生成相关血管生成素 2 相关

血友病是由于凝血因子缺乏而发生的出血性疾病,血管生成过程是血友病性关节病病理生理的重要过程。尽管今天在血友病的治疗中仍取得了非常重要的进展,但寻找能够预测关节出血和血友病长期增加的生物标志物,这继续决

HAEMOPHILIA:血友病患者的全因死亡率和死亡原因: 系统评价和META分析

A型血友病和B型血友病分别是由因子VIII(FVIII)和因子IX(FIX)缺乏引起的遗传性出血疾病

信念医药血友病基因疗法获临床试验批准,开启国内AAV基因疗法新篇章

8月6日,上海信致医药科技有限公司(信念医药全资子公司)自主研发的

NEJM:AAV基因治疗血友病,效果显著、安全性良好

血友病(Hemophilia),是一类由于血液中某些凝血因子的缺乏而导致患者产生严重凝血障碍的遗传性出血性疾病,可分为血友病A型、血友病B型和血友病C型。